CAMBRIDGE, MA – Seres Therapeutics, Inc. (NASDAQ:MCRB), a biopharmaceutical company specializing in pharmaceutical preparations, announced on Monday the appointment of Dr. Hans-Juergen Woerle as a new ...

CAMBRIDGE, Mass. - Seres Therapeutics, Inc. (NASDAQ:MCRB), a clinical-stage biotherapeutic company with a market capitalization of $133 million, announced today that it has received a $50 million ...

Seres Therapeutics, Inc. announced the receipt of a $50 million installment payment from Nestlé Health Science related to the sale of its VOWST business, contributing to the company's financial ...

Seres Therapeutics (MCRB) announced that the US Food and Drug Administration has granted Breakthrough Therapy designation to SER-155, the Company’s lead investigational program, for the ...

(RTTNews) - Seres Therapeutics, Inc. (MCRB), a commercial-stage company developing novel microbiome therapeutics for serious diseases, on Thursday announced promising new translational biomarker ...

CAMBRIDGE, Mass., Jan. 16, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB) (Seres or the Company), a leading live biotherapeutics company, announced today the receipt of a $50 ...

CAMBRIDGE, Mass., Jan. 09, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB) (Seres or the Company), a leading live biotherapeutics company, today announced new translational ...

Explore the detailed Seres Therapeutics Inc balance sheet to understand the company’s financial health and stability. This page provides a clear breakdown of key metrics, including total assets ...